BLB&B Advisors LLC Has $1.58 Million Holdings in Zimmer Biomet Holdings Inc (ZBH)

BLB&B Advisors LLC trimmed its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 5.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,045 shares of the medical equipment provider’s stock after selling 690 shares during the quarter. BLB&B Advisors LLC’s holdings in Zimmer Biomet were worth $1,584,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. MainStreet Investment Advisors LLC lifted its holdings in shares of Zimmer Biomet by 8.9% during the second quarter. MainStreet Investment Advisors LLC now owns 4,881 shares of the medical equipment provider’s stock valued at $544,000 after purchasing an additional 399 shares in the last quarter. Boltwood Capital Management lifted its holdings in shares of Zimmer Biomet by 5.7% during the third quarter. Boltwood Capital Management now owns 7,788 shares of the medical equipment provider’s stock valued at $1,023,000 after purchasing an additional 420 shares in the last quarter. Bradley Foster & Sargent Inc. CT lifted its holdings in shares of Zimmer Biomet by 6.7% during the second quarter. Bradley Foster & Sargent Inc. CT now owns 6,773 shares of the medical equipment provider’s stock valued at $755,000 after purchasing an additional 423 shares in the last quarter. TD Asset Management Inc. lifted its holdings in shares of Zimmer Biomet by 0.7% during the second quarter. TD Asset Management Inc. now owns 61,859 shares of the medical equipment provider’s stock valued at $6,894,000 after purchasing an additional 425 shares in the last quarter. Finally, MUFG Americas Holdings Corp lifted its holdings in shares of Zimmer Biomet by 18.0% during the second quarter. MUFG Americas Holdings Corp now owns 2,906 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 443 shares in the last quarter. 87.18% of the stock is currently owned by hedge funds and other institutional investors.

ZBH stock opened at $123.30 on Friday. Zimmer Biomet Holdings Inc has a fifty-two week low of $104.28 and a fifty-two week high of $134.55. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.25 and a current ratio of 2.41. The stock has a market capitalization of $26.75 billion, a price-to-earnings ratio of 15.26, a PEG ratio of 2.41 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.99 billion. During the same quarter in the prior year, the company earned $2.08 earnings per share. Zimmer Biomet’s revenue was up 3.0% on a year-over-year basis. On average, equities analysts predict that Zimmer Biomet Holdings Inc will post 7.66 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date is Thursday, September 27th. Zimmer Biomet’s dividend payout ratio is 11.96%.

A number of research analysts have recently issued reports on ZBH shares. Jefferies Financial Group upped their price target on Zimmer Biomet to $145.00 and gave the company a “buy” rating in a report on Monday, July 30th. Oppenheimer reaffirmed a “buy” rating and set a $138.00 price target (up from $130.00) on shares of Zimmer Biomet in a report on Friday, July 27th. Needham & Company LLC downgraded Zimmer Biomet from a “strong-buy” rating to a “buy” rating and set a $150.00 price target on the stock. in a report on Monday, August 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet in a report on Monday, August 27th. Finally, Canaccord Genuity upped their price target on Zimmer Biomet from $122.00 to $125.00 and gave the company a “hold” rating in a report on Monday, July 30th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $135.55.

In other Zimmer Biomet news, VP Chad F. Phipps sold 30,100 shares of the company’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Tony W. Collins sold 2,778 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $125.77, for a total value of $349,389.06. The disclosure for this sale can be found here. 0.71% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: How analysts view the yield curve

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply